Evaluation and promotion of specific adaptative immunity against polyomavirus (BKV) to prevent viral infection after kidney transplantation (BK-VAX project)

Conditions

Prevention viral infection (BKV) poliamavirus after kidney trasplantation

Brief summary

changes in immune response virus-specific at different biological levels, of patients who develop infection virus by the BK virus through the changes in BK virus viral load in peripheral blood of patients

Detailed description

Differences between groups of the specific effector polyfunctional T (IFN-y/IL2, IL-2, IFN-y, IL6, IL-4) response against different proteins VBK (LT-1, VP1) using FluorSPOT technique, Differences Between Groups in Memory B Cell Response producer of specific IgG against BKV immunogenic proteins, Differences between specific neutralizing antibodies (NAb), by using a system based on pseudovirions that express genotypes I-IV virus capsid proteins, Differences in the specific immunophenotype by FACS multiparameter spectral analysis (AURORA, CyTEX Bioscience) of cells CD8+, CD4+ and NKT with special interest in exhaustion phenotypes that could be induced by using mTor-i (CD45RA and CD27; CD85j, CD161, CD16, CD56 CD161 and CD94 and KLRG1; or PD-1, TIM-3, LAG3, and DNAM-1)., Differences in TCR signaling efficiency of cells Specific T against BKV

Related papers

No related papers found yet.

Interventions

DRUGMyfortic 360 mg Comprimidos gastrorresistentes

DRUGCellCept 250 mg capsules

DRUGCellCept 500 mg film-coated tablets

DRUGRapamune 1 mg coated tablets

DRUGMyfortic 180 mg comprimidos gastrorresistentes

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
changes in immune response virus-specific at different biological levels, of patients who develop infection virus by the BK virus through the changes in BK virus viral load in peripheral blood of patients	—

Secondary

Measure	Time frame
Differences between groups of the specific effector polyfunctional T (IFN-y/IL2, IL-2, IFN-y, IL6, IL-4) response against different proteins VBK (LT-1, VP1) using FluorSPOT technique, Differences Between Groups in Memory B Cell Response producer of specific IgG against BKV immunogenic proteins, Differences between specific neutralizing antibodies (NAb), by using a system based on pseudovirions that express genotypes I-IV virus capsid proteins, Differences in the specific immunophenotype by FACS multiparameter spectral analysis (AURORA, CyTEX Bioscience) of cells CD8+, CD4+ and NKT with special interest in exhaustion phenotypes that could be induced by using mTor-i (CD45RA and CD27; CD85j, CD161, CD16, CD56 CD161 and CD94 and KLRG1; or PD-1, TIM-3, LAG3, and DNAM-1)., Differences in TCR signaling efficiency of cells Specific T against BKV	—

Measure

Time frame

Differences between groups of the specific effector polyfunctional T (IFN-y/IL2, IL-2, IFN-y, IL6, IL-4) response against different proteins VBK (LT-1, VP1) using FluorSPOT technique, Differences Between Groups in Memory B Cell Response producer of specific IgG against BKV immunogenic proteins, Differences between specific neutralizing antibodies (NAb), by using a system based on pseudovirions that express genotypes I-IV virus capsid proteins, Differences in the specific immunophenotype by FACS multiparameter spectral analysis (AURORA, CyTEX Bioscience) of cells CD8+, CD4+ and NKT with special interest in exhaustion phenotypes that could be induced by using mTor-i (CD45RA and CD27; CD85j, CD161, CD16, CD56 CD161 and CD94 and KLRG1; or PD-1, TIM-3, LAG3, and DNAM-1)., Differences in TCR signaling efficiency of cells Specific T against BKV

—

Countries

Spain

Outcome results

None listed